Navigating the Complexity of Resistance in Lung Cancer Therapy: Mechanisms, Organoid Models, and Strategies for Overcoming Treatment Failure

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Dec 17

PMID 39682183

Authors

Da Hyun Kang

Jisoo Lee

Subin Im

Chaeuk Chung

Affiliations

Soon will be listed here.

Abstract

: The persistence of chemotherapy-resistant and dormant cancer cells remains a critical challenge in the treatment of lung cancer. Objectives: This review focuses on non-small cell lung cancer and small cell lung cancer, examining the complex mechanisms that drive treatment resistance. : This review analyzed current studies on chemotherapy resistance in NSCLC and SCLC, focusing on tumor microenvironment, genetic mutations, cancer cell heterogeneity, and emerging therapies. : Conventional chemotherapy and targeted therapies, such as tyrosine kinase inhibitors, often fail due to factors including the tumor microenvironment, genetic mutations, and cancer cell heterogeneity. Dormant cancer cells, which can remain undetected in a quiescent state for extended periods, pose a significant risk of recurrence upon reactivation. These cells, along with intrinsic resistance mechanisms, greatly complicate treatment efforts. Understanding these pathways is crucial for the development of more effective therapies. Emerging strategies, including combination therapies that target multiple pathways, are under investigation to improve treatment outcomes. Innovative approaches, such as antibody-drug conjugates and targeted protein degradation, offer promising solutions by directly delivering cytotoxic agents to cancer cells or degrading proteins that are essential for cancer survival. The lung cancer organoid model shows substantial promise to advance both research and clinical applications in this field, enhancing the ability to study resistance mechanisms and develop personalized treatments. The integration of current research underscores the need for continuous innovation in treatment modalities. : Personalized strategies that combine novel therapies with an in-depth understanding of tumor biology are essential to overcome the challenges posed by treatment-resistant and dormant cancer cells in lung cancer. A multifaceted approach has the potential to significantly improve patient outcomes.

References

Li H, Chen Z, Chen N, Fan Y, Xu Y, Xu X . Applications of lung cancer organoids in precision medicine: from bench to bedside. Cell Commun Signal. 2023; 21(1):350. PMC: 10698950. DOI: 10.1186/s12964-023-01332-9. View

Montanino A, Manzo A, Carillio G, Palumbo G, Esposito G, Sforza V . Angiogenesis Inhibitors in Small Cell Lung Cancer. Front Oncol. 2021; 11:655316. PMC: 8195287. DOI: 10.3389/fonc.2021.655316. View

Kim M, Mun H, Sung C, Cho E, Jeon H, Chun S . Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun. 2019; 10(1):3991. PMC: 6728380. DOI: 10.1038/s41467-019-11867-6. View

Uozu S, Imaizumi K, Yamaguchi T, Goto Y, Kawada K, Minezawa T . Feasibility of tissue re-biopsy in non-small cell lung cancers resistant to previous epidermal growth factor receptor tyrosine kinase inhibitor therapies. BMC Pulm Med. 2017; 17(1):175. PMC: 5719748. DOI: 10.1186/s12890-017-0514-3. View

Bollinger M, Agnew A, Mascara G . Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. J Oncol Pharm Pract. 2017; 24(5):379-388. DOI: 10.1177/1078155217712401. View

Albrengues J, Shields M, Ng D, Park C, Ambrico A, Poindexter M . Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science. 2018; 361(6409). PMC: 6777850. DOI: 10.1126/science.aao4227. View

Ott P, Wu C . Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors. Cancer Discov. 2019; 9(4):476-481. PMC: 7067230. DOI: 10.1158/2159-8290.CD-18-1357. View

Aguirre-Ghiso J . Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007; 7(11):834-46. PMC: 2519109. DOI: 10.1038/nrc2256. View

Sultana R, Chen S, Lim E, Dent R, Chowbay B . Efficacy and safety of sacituzumab govitecan Trop-2-targeted antibody-drug conjugate in solid tumors and UGT1A1*28 polymorphism: a systematic review and meta-analysis. BJC Rep. 2024; 2(1):85. PMC: 11554802. DOI: 10.1038/s44276-024-00106-1. View

10.

Takahama T, Sakai K, Takeda M, Azuma K, Hida T, Hirabayashi M . Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study). Oncotarget. 2016; 7(36):58492-58499. PMC: 5295446. DOI: 10.18632/oncotarget.11303. View

11.

Park D, Lee D, Kim Y, Park Y, Lee Y, Lee J . Cryobiopsy: A Breakthrough Strategy for Clinical Utilization of Lung Cancer Organoids. Cells. 2023; 12(14). PMC: 10377875. DOI: 10.3390/cells12141854. View

12.

Groelly F, Fawkes M, Dagg R, Blackford A, Tarsounas M . Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2022; 23(2):78-94. DOI: 10.1038/s41568-022-00535-5. View

13.

Janne P, Baik C, Su W, Johnson M, Hayashi H, Nishio M . Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, -Mutated Non-Small Cell Lung Cancer. Cancer Discov. 2021; 12(1):74-89. PMC: 9401524. DOI: 10.1158/2159-8290.CD-21-0715. View

14.

Zhou G, Guo L, Xu J, Tang K, Chen J . Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis. Ther Adv Med Oncol. 2024; 16:17588359241227677. PMC: 10832416. DOI: 10.1177/17588359241227677. View

15.

Waldmann T, Dubois S, Miljkovic M, Conlon K . IL-15 in the Combination Immunotherapy of Cancer. Front Immunol. 2020; 11:868. PMC: 7248178. DOI: 10.3389/fimmu.2020.00868. View

16.

Khan S, Fatima K, Aisha S, Malik F . Unveiling the mechanisms and challenges of cancer drug resistance. Cell Commun Signal. 2024; 22(1):109. PMC: 10860306. DOI: 10.1186/s12964-023-01302-1. View

17.

Patel S, Patel J . Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion. Adv Ther. 2023; 40(12):5579-5590. PMC: 10611612. DOI: 10.1007/s12325-023-02680-1. View

18.

Lorenz J, Blum M . Complications of percutaneous chest biopsy. Semin Intervent Radiol. 2011; 23(2):188-93. PMC: 3036363. DOI: 10.1055/s-2006-941449. View

19.

Matsuo K, Taniguchi K, Hamamoto H, Inomata Y, Komura K, Tanaka T . Delta-like canonical Notch ligand 3 as a potential therapeutic target in malignancies: A brief overview. Cancer Sci. 2021; 112(8):2984-2992. PMC: 8353941. DOI: 10.1111/cas.15017. View

20.

Schoenhals J, Seyedin S, Anderson C, Brooks E, Li Y, Younes A . Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation. Transl Lung Cancer Res. 2017; 6(2):148-158. PMC: 5420535. DOI: 10.21037/tlcr.2017.03.06. View